PD-L1: A Biomarker With Baggage

Naveed Saleh, MD, MS
Published: Thursday, Jan 30, 2020
David Rimm, MD, PhD

David Rimm, MD, PhD

Although PD-L1 expression is the most established yardstick of response to immune checkpoint immunotherapy, its clinical utility as a biomarker remains an enigma further complicated by the variety of assays and algorithms for measuring it, experts say.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication